Table 1. Targeted agents and... | American Society of Hematology

Table 1.

Targeted agents and combinations in relapsed/refractory indolent B-NHL

Study	Drug	Disease	n	ORR	CR	DOR	PFS
Witzig et al⁴	Lenalidomide	FL	22	27%	9%	NR at 16.5 mo	4.4 mo
CALGB 50401⁵	R-lenalidomide	FL	46	76%	39%	NA	24 mo
AUGMENT⁶	R-lenalidomide	FL	147
AUGMENT⁶	R-lenalidomide	MZL	31	78%	34%	36.6 mo	39.4 mo
Michot et al¹⁰	Obinutuzumab-avadomide	FL	18	83%	50%	9.8 mo	11.2 mo
DAWN¹⁵	Ibrutinib	FL	110	20.9%	11%	19.4 mo	4.6 mo
Bartlett et al¹⁶	Ibrutinib	FL	40	37.5%	12.5%	13.9 mo	14 mo
Noy et al²⁰	Ibrutinib	MZL	63	48%	11%	NR at 19.4 mo	14.2 mo
Treon et al²¹	Ibrutinib	LPL	63	90.5%	73%	NA	69.1% at 2 y
Gopal et al²⁴	Idelalisib	FL	72	57%	6%	12.5 mo	11 mo
Dreyling et al²⁶	Copanlisib	FL	104	59%	12%	22.6 mo	11.2 mo
		MZL	23	70%
		LPL	6	17%
Flinn et al²⁷	Duvelisib	FL	83	42.2%	1.6%	10 mo	9.5 mo
Flinn et al²⁷	Duvelisib	MZL	18	38.8%	1.6%	10 mo	9.5 mo
Davids et al²⁸	Venetoclax	FL	29	29%	14%	NA	11 mo
		MZL	3	67%
		LPL	4	100%
Zinzani et al²⁹	R-venetoclax	FL	53	33%	14%	NA	NA
Zinzani et al²⁹	BR-venetoclax	FL	51	68%	50%	NA	NA
Castillo et al³⁰	Venetoclax	LPL	30	80%	53%	NA	NA
Morschhauser et al³³	Tazemetostat	FL	Mut 22	82%	5%	NR at 32 wk	NA
Morschhauser et al³³	Tazemetostat	FL	WT 54	35%	6%	NR at 56 wk	NA

Study	Drug	Disease	n	ORR	CR	DOR	PFS
Witzig et al⁴	Lenalidomide	FL	22	27%	9%	NR at 16.5 mo	4.4 mo
CALGB 50401⁵	R-lenalidomide	FL	46	76%	39%	NA	24 mo
AUGMENT⁶	R-lenalidomide	FL	147
AUGMENT⁶	R-lenalidomide	MZL	31	78%	34%	36.6 mo	39.4 mo
Michot et al¹⁰	Obinutuzumab-avadomide	FL	18	83%	50%	9.8 mo	11.2 mo
DAWN¹⁵	Ibrutinib	FL	110	20.9%	11%	19.4 mo	4.6 mo
Bartlett et al¹⁶	Ibrutinib	FL	40	37.5%	12.5%	13.9 mo	14 mo
Noy et al²⁰	Ibrutinib	MZL	63	48%	11%	NR at 19.4 mo	14.2 mo
Treon et al²¹	Ibrutinib	LPL	63	90.5%	73%	NA	69.1% at 2 y
Gopal et al²⁴	Idelalisib	FL	72	57%	6%	12.5 mo	11 mo
Dreyling et al²⁶	Copanlisib	FL	104	59%	12%	22.6 mo	11.2 mo
		MZL	23	70%
		LPL	6	17%
Flinn et al²⁷	Duvelisib	FL	83	42.2%	1.6%	10 mo	9.5 mo
Flinn et al²⁷	Duvelisib	MZL	18	38.8%	1.6%	10 mo	9.5 mo
Davids et al²⁸	Venetoclax	FL	29	29%	14%	NA	11 mo
		MZL	3	67%
		LPL	4	100%
Zinzani et al²⁹	R-venetoclax	FL	53	33%	14%	NA	NA
Zinzani et al²⁹	BR-venetoclax	FL	51	68%	50%	NA	NA
Castillo et al³⁰	Venetoclax	LPL	30	80%	53%	NA	NA
Morschhauser et al³³	Tazemetostat	FL	Mut 22	82%	5%	NR at 32 wk	NA
Morschhauser et al³³	Tazemetostat	FL	WT 54	35%	6%	NR at 56 wk	NA

B-NHL, B-cell non-Hodgkin lymphoma; BR, bendamustine rituximab; CR, complete response; DOR, duration of response; FL, follicular lymphoma; LPL, lymphoplasmacytic lymphoma; MZL, marginal zone lymphoma; Mut, mutant; NA, not reported; NR, not reached; ORR, overall response rate; PFS, progression-free survival; R, rituximab; WT, wild type.

View Large

This Feature Is Available To Subscribers Only